$17.84
3.66% today
Nasdaq, Aug 12, 09:16 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$17.21
-1.10 6.01% 1M
-1.68 8.89% 6M
-1.59 8.46% YTD
-5.73 24.98% 1Y
-28.42 62.28% 3Y
-23.37 57.59% 5Y
+11.25 188.76% 10Y
-10.29 37.42% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.79 4.81%

Key metrics

Basic
Market capitalization
$2.4b
Enterprise Value
$1.6b
Net debt
positive
Cash
$1.1b
Shares outstanding
138.1m
Valuation (TTM | estimate)
P/E
negative | 407.0
P/S
4.4 | 3.0
EV/Sales
2.9 | 2.0
EV/FCF
162.3
P/B
3.5
Financial Health
Equity Ratio
16.3%
Return on Equity
-323.3%
ROCE
-8.8%
ROIC
-28.4%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$545.2m | $798.4m
EBITDA
$-97.4m | $119.3m
EBIT
$-118.6m | $186.5m
Net Income
$-144.0m | $5.8m
Free Cash Flow
$9.6m
Growth (TTM | estimate)
Revenue
1,438.0% | 22,391.3%
EBITDA
78.7% | 120.5%
EBIT
75.0% | 131.0%
Net Income
69.4% | 101.0%
Free Cash Flow
102.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-17.9% | 14.9%
EBIT
-21.7%
Net
-26.4% | 0.7%
Free Cash Flow
1.8%
More
EPS
$-1.1
FCF per Share
$0.1
Short interest
11.6%
Employees
609
Rev per Employee
$10.0k
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

15x Buy
71%
6x Hold
29%

Analyst Opinions

21 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
545 545
1,438% 1,438%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 116 116
8% 8%
21%
- Research and Development Expense 526 526
37% 37%
97%
-97 -97
79% 79%
-18%
- Depreciation and Amortization 21 21
32% 32%
4%
EBIT (Operating Income) EBIT -119 -119
75% 75%
-22%
Net Profit -144 -144
69% 69%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q3 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andy Davis - SVP of Cardiovascular & Head of Metabolic Franchise Bruce D. Given - Corporate Participant Chief Medical Scientist - Corporate Participant Christopher R.
Neutral
The Motley Fool
5 days ago
Arrowhead (ARWR) Q3 Revenue Drops 41%
Neutral
Business Wire
5 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, at 4:30 p.m. ET to discuss the results. “Arrowhead continues to achieve strong execution in discovery, clinical and regulatory, and business development...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today